BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
ALT upcoming catalysts
Altimmune, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 0 FDA event(s). Subscribe to ALT (.ics).
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|
| No upcoming PDUFA date or AdCom found. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| No trials in this window. |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|
| No FDA decision events in this window. |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-07-30 | P2 | Altimmune, Inc. ALT | NCT06987513 RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight | Alcohol Use Disorder (AUD) | completed | 100 |
| 2025-11-25 | P2 | Altimmune, Inc. ALT | NCT05989711 IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) | Non-Alcoholic Steatohepatitis (NASH) | completed | 212 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.